Trade Names:Cogentin- Tablets 0.5 mg- Tablets 1 mg- Tablets 2 mg- Injection 1 mg/mLApo-Benztropine (Canada)
Thought to act by competitively antagonizing acetylcholine receptors in corpus striatum to restore neuromuscular balance.
Treatment of all forms of parkinsonism; control of extrapyramidal disorders (except tardive dyskinesia) caused by neuroleptic drugs.
Angle-closure glaucoma; myasthenia gravis; pyloric or duodenal obstruction; stenosing peptic ulcer; prostatic hypertrophy or bladder neck obstructions; megacolon; tardive dyskinesia; children under 3 yr of age.
PO 1 to 2 mg/day; range, 0.5 to 6 mg. Individualize dosage.Idiopathic ParkinsonismAdults
PO Initially 0.5 to 1 mg at bedtime; 4 to 6 mg/day may be required.Postencephalitic ParkinsonismAdults
PO 2 mg/day in 1 or more doses; some patients may require initial dose of 0.5 mg.Drug-Induced Extrapyramidal DisordersAdults
1 to 4 mg every day or twice daily.Acute Dystonic ReactionsAdults
PO / IM / IV Initial dose is IM / IV 1 to 2 mg; then PO 1 to 2 mg twice daily.
Store in a dry place in tightly closed, light-resistant container.
May increase anticholinergic effects.Digoxin
May increase digoxin serum levels, especially with slow-dissolution oral digoxin tablets.Haloperidol
May worsen schizophrenic symptoms; may decrease haloperidol serum levels; tardive dyskinesia may develop.Phenothiazines
May decrease action of phenothiazines. May increase incidence of anticholinergic effects.
None well documented.
Toxic psychosis including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of pre-existing psychosis; nervousness; depression; finger numbness.
Blurred vision; dilated pupils; narrow-angle glaucoma.
Paralytic ileus; constipation; nausea; vomiting; dry mouth.
Urinary retention; dysuria.
Heat stroke; hyperthermia; fever; weakness; inability to move particular muscle groups.
Category C .
Safety and efficacy not established
Patients above 60 yr of age may have increased side effects; dosage reduction and observation may be needed.
Use with caution in patients with glaucoma, prostatic hypertrophy, epilepsy, cardiac arrhythmias, hypertension, hypotension, tendency toward urinary retention, liver or kidney disorders, obstructive disease of GI or GU tract, tachycardia or those who are taking other drugs with anticholinergic activity.
Fatal hyperthermia has occurred. Use with caution during hot weather.
Narrow-angle glaucoma may occur.
May aggravate tardive dyskinesia.
Circulatory collapse, cardiac arrest, respiratory depression, CNS depression or stimulation, shock, coma, stupor, seizures, convulsions, ataxia, anxiety, incoherence, hyperactivity, foul-smelling breath, decreased bowel sounds, dilated and sluggish pupils.
Copyright © 2009 Wolters Kluwer Health.